Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, SGLT2i Jun 08 | 2019Novo Oral Sema Data, Tirzepatide Ph2 Analyses, New Medtronic Pivotal Studies; ADA 2019 Key Press Releases (June 8)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Jun 07 | 2019Tidepool Partners with Medtronic and Dexcom; ADA 2019 Key Press Releases (June 7)Purchase BlastFree
Posted in: Basal Insulin, Bolus Insulin, Glucagon, Glucose Monitoring, Insulin Delivery, Other Jun 06 | 2019New Sanofi CEO; Xeris delayed: SENS approval, InPen-Dexcom; Zeal-BB; vTv; AdociaAccess Free Blast$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jun 06 | 2019ADA ’19 Key Data and Partnership Press Releases (June 5)Purchase Blast
$599
Posted in: DPP-IVi, SGLT2i Jun 04 | 2019BI/Lilly Empa+Lina+MetXR Triple FDC Filing Accepted By FDAPurchase Blast
$599
Posted in: GLP-1RA Jun 03 | 2019REWIND: FENIX Team Split – Matt’s Bold Prediction vs. Team ConsensusPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 30 | 2019FENIX Analysis: Devices Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 23 | 2019Medtronic CY Q1 '19 (FY Q4 '19) Earnings UpdatePurchase Blast
$599
Posted in: Glucagon, Insulin Delivery May 22 | 2019Zealand/Beta Bionics Initiate iLet In-home Closed-Loop TrialPurchase Blast
$599
Posted in: Bolus Insulin May 22 | 2019Lilly's Lispro Authorized Generic Now Available in US PharmaciesPurchase Blast
Free
Posted in: SGLT2i May 22 | 2019CREDENCE Priority Review for Invokana; PDUFA Projected in Late September 2019Access Free Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA + Basal May 21 | 2019FENIX Analysis: Insulin Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 21 | 2019Glooko Appoints Mark Clements as CMOPurchase Blast
Free
Posted in: Glucose Monitoring May 21 | 2019Lifescan Enters CGM Market with New Partnership; Ty Lee Returns to LifescanAccess Free Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery May 17 | 2019FDA Warns Against DIY Closed-Loop SystemsPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA May 17 | 2019New Tirzepatide vs. Semaglutide Ph1 T2DM Clamp Study; Ph3 SURPASS-1 Monotherapy Trial InitiatedPurchase Blast$599
Posted in: SGLT2i May 16 | 2019FENIX Analysis: SGLT2i Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Dual/triple agonist, Glucagon May 16 | 2019Zealand Q1 '19 Earnings UpdatePurchase Blast